Navigation Links
Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
Date:10/25/2010

ire.com/designimages/widetable-release.JPG" style="border:0px" alt="Click to view news release full screen">  

Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy

 

AMSTERDAM, October 25, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the development of gene based therapies, today announced that its gene therapy product incorporating
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
3. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
7. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
8. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
9. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
10. New Data Suggest Veracytes Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples
11. Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... announced that longer-term toxicology studies for its newly ... arthritis, or RA, have been completed. The results ... the U.S. Food and Drug Administration. The feedback ... completion of the ongoing first-in-human study. Additional preclinical ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)... 2015  Steep Hill, the industry leader in cannabis ... to open a full service medical cannabis quality assurance ... bringing advanced scientific tools and methodology to the state, ... is currently the only laboratory licensed by the New ... testing in order to meet the recently adopted regulatory ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... Radiology Group Improves Physician Efficiency and Reduces Duplicative ... ... CHICAGO, Nov. 26 RSNA Booth #5924 -- Compressus ... in Illinois, announced today that ARC has improved physician,efficiency and ...
... Million for Q3 of 2007 versus $5.2 Million ... for Q3 of 2006, -- Gross profit increases 102% ... ... of $12.5 Million of Debt to Equity, BEIJING, Nov. 23 /Xinhua-PRNewswire/ -- China Biopharmaceuticals,Holdings, ...
... and PARIS, Nov. 23 Bristol-,Myers Squibb Company ... reported today,that they are terminating their license agreement ... investigation for the treatment of,advanced or metastatic bladder ... Pierre Fabre Medicament and licensed to Bristol-Myers Squibb,in ...
Cached Biology Technology:Diagnostic Turnaround Improved by 600% Through Interoperability 2Diagnostic Turnaround Improved by 600% Through Interoperability 3Diagnostic Turnaround Improved by 600% Through Interoperability 4China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 2China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 3China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 4China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 5China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 6China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 7
(Date:2/10/2015)... -- Alere Inc. (NYSE: ALR), a global leader in ... quarter ended December 31, 2014. Namal ... said, "We made substantial progress in the fourth ... in rapid diagnostics and delivering against our financial ... early January enabled us to substantially reduce our ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... ) as part of its 2015 marketing and branding ... its new consumer website for Wocketwallet.com earlier this month. ... NXT-ID said, "Our new corporate website naturally showcases our ...
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... DALLAS Nov. 12, 2007 Human lung-cancer tumors grown ... treated with a synthetic compound that mimics the action of ... UT Southwestern Medical Center report. The findings, appearing in ... compound might one day be used in targeted therapies for ...
... On September 10, 2007, ConsumerLab.com issued ... contain label amounts of folic acid. One of these ... part of U. S. Pharmacopeias (USP) Dietary Supplement Verification ... to the report, USP studied the verified product to ...
... to stopping Alzheimers disease" A new research study from ... could offer a way to blunt or even prevent ... mice with a protein believed to play a key ... the vaccination showed a significant reduction in the build-up ...
Cached Biology News:Synthetic compound promotes death of lung-cancer cells, tumors 2Synthetic compound promotes death of lung-cancer cells, tumors 3Market testing of dietary supplements and drugs underscores value of USP's public health programs 2An Alzheimer's vaccine? 2An Alzheimer's vaccine? 3
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (Z71,517-4) or contact ... cap polystyrene (expanded surface, easy grip) ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: cap ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,704-5) ... assistance. ...
Biology Products: